Vaccination

Global Hair Care Appliances Market Forecast to 2028 - Featuring Revlon, Koninklijke Philips, Dyson, Jemella and Kiss Products Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 4, 2022
Cosmetics, Retail, Other Retail, Fashion, Online, Distribution, Man, MEA, CNN International Europe/Middle East/Africa, CAGR, Geography, Supermarket, Woman, Vaccination, COVID-19, Pharmaceutical industry, Beauty salon, Retail

The hair care appliances market is expected to grow from US$ 14,440.23 million in 2022 to US$ 19,512.86 million by 2028; it is estimated to grow at a CAGR of 5.1% from 2022 to 2028

Key Points: 
  • The hair care appliances market is expected to grow from US$ 14,440.23 million in 2022 to US$ 19,512.86 million by 2028; it is estimated to grow at a CAGR of 5.1% from 2022 to 2028
    Hair care appliances are used for hair care and hair styling.
  • The growing emphasis and focus on self-grooming and personal appearance have increased the demand for hair care appliances.
  • Based on distribution channel, the hair care appliances market is segmented into supermarkets and hypermarkets, specialty stores, online retail, and others.
  • Online retail stores offer various hair care appliances with discounts, and consumers can conveniently buy desirable products remotely.

NORWEGIAN CRUISE LINE TO ELIMINATE COVID-19 TESTING, MASKING AND VACCINATION REQUIREMENTS BEGINNING OCT. 4, 2022

Retrieved on: 
Monday, October 3, 2022
YouTube, News, Freedom, Documentation, Vaccination, Norwegian Cruise Line, Industry, Health, Twitter, Multimedia, Global health, Instagram, COVID-19, COVID-19 testing, NCL, Safety, Travel, Revolution, Cruise line, Company, Pharmaceutical industry, Tourism, Facebook

MIAMI, Oct. 3, 2022 /PRNewswire/ -- Norwegian Cruise Line (NCL), the innovator in global cruise travel, today announced that it has updated its global health and safety protocols by removing all COVID-19 testing, masking and vaccination requirements effective Oct. 4, 2022.

Key Points: 
  • MIAMI, Oct. 3, 2022 /PRNewswire/ -- Norwegian Cruise Line (NCL), the innovator in global cruise travel, today announced that it has updated its global health and safety protocols by removing all COVID-19 testing, masking and vaccination requirements effective Oct. 4, 2022.
  • "Health and safety are always our first priority; in fact, we were the health and safety leaders from the very start of the pandemic," said Harry Sommer, Norwegian Cruise Line president and chief executive officer.
  • As the innovator in global cruise travel, Norwegian Cruise Line has been breaking the boundaries of traditional cruising for 55 years.
  • For the latest news and exclusive content, visit the NCL Newsroom and follow Norwegian Cruise Line on Facebook, Instagram, Tik Tok and YouTube @NorwegianCruiseLine; and Twitter @CruiseNorwegian.

Global Genome Sequencing Market Report 2022: Pharmaceutical Evolution Drives Sector Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, October 3, 2022
Health, General Health, Cancer, Government, Conditional sentence, Vaccination, Technology, Gene, Drug discovery, CAGR, Degenerative disease, PCR, Microarray, COVID-19, National Institutes of Health, Infection, Health, Growth, RNA, Application, DNA sequencing, International Nucleotide Sequence Database Collaboration, Diagnosis, National, DNA, Therapy, Genome, Vaccine, Antibiotics

Global genome sequencing market is anticipated to grow with an impressive CAGR during the forecast years on the grounds of growing technological advancement in genetic sequencing and bioinformatics.

Key Points: 
  • Global genome sequencing market is anticipated to grow with an impressive CAGR during the forecast years on the grounds of growing technological advancement in genetic sequencing and bioinformatics.
  • Surge in the demand for the advanced pharmaceuticals and evolving infectious diseases further drive the growth of the global genome sequencing market in the upcoming five years.
  • With consistent supply of financial funds from the government and higher research scope in the technology also supports the growth of the global genome sequencing market in the next five years.
  • Advancement in the biotechnological procedures and microbiology studies add to the growth of the global genome sequencing market in the upcoming five years.

Roche launches its next-generation SARS-CoV-2 Rapid Antibody Test

Retrieved on: 
Monday, October 3, 2022
Solution, Serology, Vaccine, RO, Polymerase chain reaction, Johnson & Johnson, Serum, Vaccination, Immunity, Research, Severe acute respiratory syndrome coronavirus 2, Clinical trial, ROG, Blood, World Health Organization, Immunoglobulin G, CE marking, Antibody, World, IL-6, PCR, COVID-19, AstraZeneca, Infection, Disease management, Medicine, Hoffmann-La Roche, Immunoassay, Partnership, Health care, Literature, Roche Diagnostics, Policy, Dow Jones, Genentech, Pass, Union, Plasma, Pfizer–BioNTech COVID-19 vaccine, Casirivimab/imdevimab, Patient, Pharma, Regeneron Pharmaceuticals, SD, Awareness, Point, Pharmaceutical industry, Fine chemical, Tutoring, Diagnosis, Chugai Pharmaceutical Co.

ROTKREUZ, Switzerland, Oct. 3, 2022 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the SARS-CoV-2 Rapid Antibody Test 2.0 in markets accepting the CE Mark.

Key Points: 
  • ROTKREUZ, Switzerland, Oct. 3, 2022 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the SARS-CoV-2 Rapid Antibody Test 2.0 in markets accepting the CE Mark.
  • The test is the next generation of Roche's existing SARS-CoV-2 Rapid Antibody Test, which launched in July 2020.
  • "The next-generation of our SARS-CoV-2 Rapid Antibody Test demonstrates Roche's continued commitment to innovate as the COVID-19 pandemic evolves," said Ian Parfrement, Head of Point of Care at Roche Diagnostics.
  • Roche's SARS-CoV-2 Rapid Antibody Test 2.0 is a rapid chromatographic immunoassay intended for qualitative detection of IgG antibodies to SARS-CoV-2 in human serum, plasma or whole blood.

The Fenway Institute Offers Recommendations for Improving Human Papillomavirus Vaccination Rates in US

Retrieved on: 
Sunday, October 2, 2022
Adult, Wart, ACIP, Health, Safety, Sex, LGBT, Anal cancer, COVID-19, Woman, STI, Vaccination, HIV, Population, Life, Loyola University Chicago, Loyola University, Stritch School of Medicine, Patient, White, Fenway Health, Fenway Park, Advisory Committee, Human papillomavirus infection, Vaccine, Head, Federally Qualified Health Center, Gender identity, HPV, Stockholm Environment Institute US Center, Research, Ageing, Parent, PDF, Human, Awareness, Man, Neck, Policy

BOSTON, October 02, 2022  /PRNewswire-PRWeb/ -- A policy brief published by The Fenway Institute at Fenway Health offers recommendations to health professionals and policy makers on how to improve Human Papillomavirus (HPV) vaccination rates in the U.S. HPV is the most common sexually transmitted infection (STI) in the world. Approximately 79 million Americans, most in their teens and early 20s, are infected with HPV despite the widespread availability of a safe and effective vaccine since 2006.

Key Points: 
  • But vaccination rates remain far below optimal rates of coverage, especially among male-identifying individuals.
  • There are other disparities in vaccination rates across populations of varying sexual and gender identities, as well as race and ethnicity.
  • The policy brief, titled "Improving Human Papillomavirus vaccination rates in the U.S.: Recommendations for health professionals and policy makers," addresses barriers to HPV vaccination, including the politicization of vaccines, sex and gender-based stigma, medical mistrust, misinformation, and insufficient provider recommendation.
  • "Improving Human Papillomavirus vaccination rates in the U.S.: Recommendations for health professionals and policy makers," is available for download as a PDF here .

Bio Farma secures multi-year Purchase Contract from UNICEF for its novel Oral Polio Vaccine type 2 (nOPV2)

Retrieved on: 
Sunday, October 2, 2022
EUA, Indonesian Ulema Council, Food, UNICEF, COVID-19, World, G20, World Health Organization, Vaccination, Pharmacy, PEHA, Certification, Laboratory, Bio Farma, Vaccine, Public health, EUL, BMGF, PATH, Emergency Use Authorization, WHO, OPV, IDX, Bill & Melinda Gates Foundation, Oral polio vaccine AIDS hypothesis, Animal, Pharmaceutical industry, Radical honesty

BANDUNG, INDONESIA, Oct 2, 2022 - (ACN Newswire) - PT Bio Farma (Persero), the holding company for pharmaceutical state-owned enterprises (SOEs), will export its novel Oral Polio Vaccine type 2 (nOPV2) having secured a purchase contract with the United Nations Children's Fund (UNICEF) for 2022 & 23.

Key Points: 
  • BANDUNG, INDONESIA, Oct 2, 2022 - (ACN Newswire) - PT Bio Farma (Persero), the holding company for pharmaceutical state-owned enterprises (SOEs), will export its novel Oral Polio Vaccine type 2 (nOPV2) having secured a purchase contract with the United Nations Children's Fund (UNICEF) for 2022 & 23.
  • Under the contract, Bio Farma will export its oral polio vaccines based on purchase requests from UNICEF via multilateral contract agreement for the years 2022 & 23.
  • Honesti Basyir, President Director of Bio Farma, said, "UNICEF procures nOPV2 under a multilateral supply agreement as part of a global effort to prevent spread of the polio disease.
  • In manufacturing the nOPV2 vaccine, Bio Farma collaborated with world-class institutions like the Bill and Melinda Gates Foundation (BMGF), the PATH, and the WHO.

COVID-19 Vaccine Boosters Perspectives Survey Demonstrates the Importance of Vaccination and Booster Rates Among the U.S. Paralysis Community

Retrieved on: 
Friday, September 30, 2022
Government, Faculty, FS, Health, Peabody College, ACL, Safety, Better Business Bureau, Engineering, PQP, Christopher and Dana Reeve Foundation, COVID-19, Disability, Distrust, Spinal cord, NPRC, Community Living British Columbia, Administration, Vaccination, Association of Academic Physiatrists, BBB, Lists of diseases, Rehabilitation psychology, Learning, Policy, COVID, Person, Patient, PWD, SHORT, Vanderbilt, Paralysis, PWP, Student, Quality of life, Vaccine, Public health, Friends, Anxiety, Administration for Community Living, Caregiver, Nursing, Vanderbilt University, Music, Research, Medicine, Community, Education, Pharmaceutical industry, Residential care

NASHVILLE, Tenn, and SHORT HILLS, N.J., Sept. 30, 2022 /PRNewswire/ -- Newly published research from Vanderbilt University's Peabody College and the Christopher & Dana Reeve Foundation highlights the perspectives of the paralysis community on COVID-19 vaccine boosters. Among the key findings is evidence that individuals living with paralysis have specific safety concerns that should be addressed through important doctor-patient communication – especially as the nation considers recommending yearly booster shots.

Key Points: 
  • Between December 2021 - January 2022, the Reeve Foundation distributed a survey to the paralysis community via email.
  • The survey, which included 44 questions, was aimed at learning about how informed the paralysis community is about the boosters, hesitancies about the boosters, and vaccination and booster rates.
  • PWD were significantly more likely than members of the FS group to have spoken to a provider about the boosters.
  • PWP expressed unique concerns related to paralysis or other neurological symptoms, and believed that the booster would affect their paralysis.

Sweden Construction Market Size, Trends and Forecasts 2022-2026 - ResearchAndMarkets.com

Retrieved on: 
Friday, September 30, 2022
Other Construction & Property, Residential Building & Real Estate, Commercial Building & Real Estate, Construction & Property, RRF, Construction, SCB, Risk, Swedish Maritime Administration, Vaccination, European Commission, Growth, Assessment, Industry, Forecasting, Electricity, Yoy, Commercial, Sector, Royal commission, Renewable energy, Oil, Risk management

The "Sweden Construction Market Size, Trends and Forecasts by Sector - Commercial, Industrial, Infrastructure, Energy and Utilities, Institutional and Residential Market Analysis, 2022-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Sweden Construction Market Size, Trends and Forecasts by Sector - Commercial, Industrial, Infrastructure, Energy and Utilities, Institutional and Residential Market Analysis, 2022-2026" report has been added to ResearchAndMarkets.com's offering.
  • The Swedish construction industry is expected to grow by 1.5% in real terms in 2022, following marginal growth of 0.4% in 2021 and 0.9% in 2020.
  • Historical (2017-2021) and forecast (2022-2026) valuations of the construction industry in Sweden, featuring details of key growth drivers.
  • Assess market growth potential at a micro-level with over 600 time-series data forecasts.

Bulgaria Construction Market Size, Trends and Forecast Report 2022-2026 - ResearchAndMarkets.com

Retrieved on: 
Friday, September 30, 2022
Architecture, Other Construction & Property, Residential Building & Real Estate, Commercial Building & Real Estate, Construction & Property, Building Systems, Urban Planning, Energy and Utility Skills, Construction, COVID-19, Social, Risk, National Statistical Institute (Bulgaria), Vaccination, Growth, NSI, Industry, Government, GDP, Yoy, Commercial, Sector, Research, Education, Animal, Oil, Renewable energy, EU, Coronavirus

The "Bulgaria Construction Market Size, Trends and Forecast by Sector - Commercial, Industrial, Infrastructure, Energy and Utilities, Institutional and Residential Construction, 2022-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Bulgaria Construction Market Size, Trends and Forecast by Sector - Commercial, Industrial, Infrastructure, Energy and Utilities, Institutional and Residential Construction, 2022-2026" report has been added to ResearchAndMarkets.com's offering.
  • The Bulgarian construction industry declined by an estimated 6.4% in real terms in 2021.
  • The country's construction production index also declined by 4.5% YoY in October 2021, with that of buildings construction declining by 4.5% and civil engineering construction falling by 4.5%, according to NSI.
  • The construction industry is forecast to recover in 2022, with growth of 8.3% in real terms.

Coastal Medical Transportation Systems Announces Agreement to Expand Ambulance Network

Retrieved on: 
Friday, September 30, 2022
Other Transport, Infectious Diseases, Other Health, Health, Transport, Gaps, Fallon, Efficiency, COVID-19, Ambulance, Coast, Emergency medical services, LLC, Advanced life support, Organization, Vaccination, Acquisition, Basic life support, Patient, CMTS, CEO, Technology, Solution, Transport, Boston Metro, EMS, Heel, ALS, COVID-19 testing, BLS, Communication, Hospital, Pharmaceutical industry, Central Massachusetts

Coastal Medical Transportation Systems (CMTS), a privately owned and operated medical transportation company dedicated to providing the highest quality of care with compassion, dignity and respect for customers and their patients, and Transformative Healthcare , today announced they have reached an agreement to acquire Transformative Healthcare s Massachusetts medical transportation arm, comprised of Fallon Ambulance Service and LifeLine Ambulance Service .

Key Points: 
  • Coastal Medical Transportation Systems (CMTS), a privately owned and operated medical transportation company dedicated to providing the highest quality of care with compassion, dignity and respect for customers and their patients, and Transformative Healthcare , today announced they have reached an agreement to acquire Transformative Healthcare s Massachusetts medical transportation arm, comprised of Fallon Ambulance Service and LifeLine Ambulance Service .
  • The Coastal family is excited to welcome Fallon and LifeLine Ambulance Service's valued employees and medical transportation customers into our organization, said Alex Theoharidis, Founder and Chief Executive Officer of Coastal Medical Transportation Systems.
  • The addition of the Transformative Healthcare medical transportation operation will expand the CMTS service area to collectively cover the Cape and the Islands, South Shore, Boston Metro, and Central Massachusetts regions.
  • Founded in 2013, Coastal Medical Transportation Services, LLC is a 24/7 non-emergency transportation service serving healthcare institutions and patients across New England.